Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$806.06 USD

806.06
3,726,192

-0.08 (-0.01%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $804.12 -1.94 (-0.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Lilly (LLY) COVID-19 Antibody Bamlanivimab Gets CHMP Nod

CHMP recommends approval of Eli Lilly's (LLY) COVID-19 antibody bamlanivimab, alone and in combination with etesevimab in Europe.

Eli Lilly (LLY) Stock Moves -0.72%: What You Should Know

Eli Lilly (LLY) closed the most recent trading day at $200.54, moving -0.72% from the previous trading session.

Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).

Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

Why Is Lilly (LLY) Down 2.5% Since Last Earnings Report?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

Eli Lilly (LLY) closed at $204.89 in the latest trading session, marking a +0.52% move from the prior day.

Radius' (RDUS) Q4 Loss Wider Than Expected, Revenues Beat

Radius (RDUS) reports a wider loss but beats sales estimates in the fourth quarter.

Nektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On Track

Nektar (NKTR) reports encouraging fourth-quarter 2020 results. The company plans to initiate a new registrational study on its lead pipeline candidate, bempegaldesleukin, in 2021.

United Therapeutics (UTHR) Q4 Earnings Miss, Sales Beat

United Therapeutics' (UTHR) fourth-quarter earnings miss estimates while sales beat the same. Higher sales of Orenitram, Remodulin and Tyvaso offset lower sales of Unituxin and Adcirca.

Benjamin Rains headshot

2 Large Cap Stocks to Buy for Income and Growth Amid Tech Volatility

Investors might want to add a few large cap names outside of the tech world that also provide income through solid dividend yields...

Kinjel Shah headshot

FDA Issues New Guidelines for COVID-19 Vaccines, Tests, Drugs

The FDA encourages companies to evaluate the impact of COVID-19 virus variants on the efficacy or performance of their COVID-19 vaccines, tests and medicines.

RedHill (RDHL) Doses First Patient in Phase II/III COVID-19 Study

RedHill (RDHL) doses first patient in phase II/III study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic COVID-19 who do not require hospital care.

Kinjel Shah headshot

Pharma Stock Roundup: Coronavirus Vaccine Updates From PFE, AZN & JNJ

WHO authorizes emergency use of AstraZeneca's (AZN) COVID-19 vaccine. J&J (JNJ) seeks conditional approval for its COVID-19 vaccine in EU.

Nektar (NKTR) Teams Up With Merck for Head & Neck Cancer Study

Nektar's (NKTR) shares up following a deal with Merck for a combination study of bempegaldesleukin with Keytruda for advanced head and neck cancer study.

Benjamin Rains headshot

3 Great Blue Chip Dividend Stocks to Buy Now with Dow at Records

Investors should always be on the lookout for ways to diversify and bolster their portfolios. One great place to start is with large cap stocks that pay solid dividends...

The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis

The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis

Kinjel Shah headshot

Pharma Stock Roundup: AZN's Q4 Earnings, FDA Approval for LLY & SNY's Drugs

AstraZeneca (AZN) announces Q4 results. FDA approves Lilly's COVID-19 antibody cocktail & Sanofi's (SNY) Libtayo for a new indication.

Lilly (LLY) COVID-19 Antibody Combo Gets FDA's Emergency Nod

FDA grants EUA to Eli Lilly's (LLY) COVID-19 antibody cocktail. FDA also authorizes shortened infusion time for bamlanivimab/etesevimab.

ABBV or LLY: Which Is the Better Value Stock Right Now?

ABBV vs. LLY: Which Stock Is the Better Value Option?

Sweta Killa headshot

Pharma ETFs in Focus Post Q4 Earnings

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, MRK Q4 Earnings, AZN, JNJ Coronavirus Vaccine Updates

Several companies announce Q4 results. J&J (JNJ) and AstraZeneca (AZN) provide updates on their respective COVID-19 vaccines.

The Zacks Analyst Blog Highlights: Adobe, Toyota Motor, QUALCOMM, Eli Lilly and PetroChina

The Zacks Analyst Blog Highlights: Adobe, Toyota Motor, QUALCOMM, Eli Lilly and PetroChina

Sheraz Mian headshot

Top Analyst Reports for Adobe, Toyota & QUALCOMM

Today's Research Daily features new research reports on 16 major stocks, including Adobe (ADBE), Toyota (TM), and QUALCOMM (QCOM).

Tiziana (TLSA) Posts Positive Data on Nasal COVID-19 Antibody

Tiziana (TLSA) reports positive data from a study investigating its anti-CD3 human monoclonal antibody, foralumab (nasally administered) for treating COVID-19 patients in Brazil. Shares up.

Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates

Novo Nordisk (NVO) beats both earnings and sales estimates for the fourth quarter of 2020.